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Abstract
Introduction Maternal metabolism changes substantially during pregnancy. However, few studies have used metabolomics 
technologies to characterize changes across gestation.
Objectives and methods We applied liquid chromatography–mass spectrometry (LC–MS) based non-targeted metabolomics 
to determine whether the metabolic profile of serum differs throughout the pregnancy between pre-eclamptic and healthy 
women in the FINNPEC (Finnish Genetics of Preeclampsia Consortium) Study. Serum samples were available from early 
and late pregnancy.
Results Progression of pregnancy had large-scale effects to the serum metabolite profile. Altogether 50 identified metabolites 
increased and 49 metabolites decreased when samples of early pregnancy were compared to samples of late pregnancy. The 
metabolic signatures of pregnancy were largely shared in pre-eclamptic and healthy women, only urea, monoacylglyceride 
18:1 and glycerophosphocholine were identified to be increased in the pre-eclamptic women when compared to healthy 
controls.
Conclusions Our study highlights the need of large-scale longitudinal metabolomic studies in non-complicated pregnancies 
before more detailed understanding of metabolism in adverse outcomes could be provided. Our findings are one of the first 
steps for a broader metabolic understanding of the physiological changes caused by pregnancy per se.
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SD  Relative birth weight
VIP  Variable importance to the projection
1 Introduction
Over the course of pregnancy, mothers face a unique physi-
ological challenge that requires complex metabolic adapta-
tions to support fetal growth and development (Lain and 
Catalano 2007). Profound changes in carbohydrate, fat, 
and protein metabolism have been reported (Butte 2000; 
Lain and Catalano 2007; Hadden and McLaughlin 2009). 
Changes in insulin sensitivity are a hallmark of pregnancy 
and contribute to the metabolic changes, while nutrient 
transfer to the fetus are thought to impact the maternal 
metabolite levels (Hadden and McLaughlin 2009; Catalano 
2014). However, studies utilizing metabolomics technolo-
gies to characterize maternal metabolism during pregnancy 
are still relatively few (Lowe and Karban 2014; Zhao et al. 
2019). New technologies allow more detailed characteriza-
tion of metabolic profiles in uncomplicated pregnancies. 
This may also advance more comprehensive understanding 
of the pathophysiology of pre-eclampsia (PE), which is a 
common vascular pregnancy complication associated with 
exaggareted metabolic changes (Von Versen-Hoeynck and 
Powers 2007).
We applied liquid chromatography–mass spectrometry 
(LC–MS) based non-targeted metabolomics to determine 
whether the metabolic profile of serum differs throughout 
the pregnancy between women with and without PE in the 
FINNPEC (Finnish Genetics of Preeclampsia Consortium) 
study.
2  Methods
2.1  Study cohort and serum samples
FINNPEC is a cross-sectional case–control multicentre 
study with a nationwide clinical and DNA database on 
women with and without PE, including their partners and 
newborns. Data of the prospective arm was assembled in 
Finland between 2008 and 2011. Details of the study design, 
methods and procedures have been described elsewhere 
(Jääskeläinen et al. 2016). PE was defined as hypertension 
and proteinuria occurring after 20 weeks gestation accord-
ing to the modified American College of Obstetricians and 
Gynecologists (ACOG) 2002 criteria. Hypertension was 
defined as systolic blood pressure ≥ 140 mm Hg or diastolic 
blood pressure ≥ 90 mm Hg. Proteinuria was defined as the 
urinary excretion of ≥ 0.3 g protein in a 24-h specimen, or 
0.3 g/L, or two ≥ 1 + readings on a dipstick in a random urine 
determination with no evidence of a urinary tract infection. 
Women with PE superimposed on chronic hypertension 
were included in the cases. Exclusion criteria were multiple 
pregnancy, maternal age < 18 years and the inability to pro-
vide an informed consent based on information in Finnish 
or Swedish.
The FINNPEC study protocol was approved by the 
coordinating Ethics Committee of the Hospital District 
of Helsinki and Uusimaa. All participants provided writ-
ten informed consent. All experiments were performed in 
accordance with relevant guidelines and regulations.
Early and late pregnancy serum samples were collected 
from a subcohort from the Hospital District of Helsinki and 
Uusimaa. Early pregnancy serum samples were obtained via 
first trimester biochemical screening for fetal chromosome 
abnormalities (range 10–15 weeks of gestation), and late 
pregnancy (range 23–41 weeks of gestation) serum samples 
were collected at hospitals. The samples were collected in 
the 10 ml serum tubes, centrifuged, the serum was removed 
and stored at − 80 °C.
For the current LC–MS metabolite profiling analysis, 
we selected samples of mothers who were non-smoking. 
Furthermore, all women included in the current study were 
Finnish in origin. In addition, pre-existing diseases (chronic 
hypertension, pregestational diabetes and gestational diabe-
tes) were exclusion criteria for healthy control women. There 
were 47 and 53 samples available from early pregnancy and 
57 and 14 samples from late pregnancy for PE and healthy 
women, respectively. Serum samples were available at both 
timepoints from 47 PE women and from 13 healthy women.
2.2  Non‑targeted LC–MS metabolite profiling
The sample preparation, instrument parameters and process-
ing of data were performed in the LC–MS Metabolomics 
Center at Biocenter Kuopio (University of Eastern Finland). 
The detailed protocol has been published earlier (Jääskel-
äinen et al. 2018; Klåvus et al. 2020). Shortly, the serum 
samples were analyzed by the UHPLC-qTOF-MS system 
(Agilent Technologies, Waldbronn, Karlsruhe, Germany) 
that consisted of a 1290 LC system, a Jetstream electrospray 
ionization (ESI) source, and a 6540 UHD accurate-mass 
qTOF spectrometer.
The analysis order of the serum samples was randomized. 
100 μL of each sample was mixed by pipette with 400 μL of 
acetonitrile (ACN, LC–MS grade), incubated on an ice bath 
for 15 min and centrifuged. The supernatant was filtered and 
collected on a 96-well plate. The samples were analyzed 
using two different chromatographic techniques, i.e. reversed 
phase (RP) and hydrophilic interaction (HILIC) chromatog-
raphy. Data were acquired in both positive (+) and negative 
(−) polarity. The sample tray was kept at 4 °C during the 
analysis. The data acquisition software was MassHunter 
Acquisition B.04.00 (Agilent Technologies). The quality 
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control and the blank samples were injected after every 12 
samples and also in the beginning of the analysis. The qual-
ity control samples were composed by pooling together a 
small aliquot of all the study samples.
Data were collected with “Find by Molecular Feature” 
algorithm in MassHunter Qualitative Analysis B.07.00 soft-
ware (Agilent Technologies, USA). The extraction algorithm 
was set to collect peaks with threshold at 200 counts for 
HILIC and 150 for RP chromatography, and the allowed ion 
species were [M + H]+, [M + Na]+, [M + K]+, [M + NH4]+, 
and [2  M + H]+ in ESI(+), and [M − H]−, [M + Cl]−, 
[M + HCOO]−, [M + CF3COO]−, and [2  M − H]− in 
ESI(−). Only signals over compound height threshold of 
3000 counts containing at least two ions were included in the 
compound list. Peak spacing tolerance for isotope grouping 
was 0.0025 m/z plus 7 ppm, with isotope model for common 
organic molecules. Data files (.cef-format) were exported to 
Mass Profiler Professional (Agilent Technologies) for peak 
alignment. After the first initial alignment, the data were 
combined in one .cef file, against which the original raw 
data was reanalyzed. For this recursive analysis, compound 
mass tolerance was ± 15 ppm, retention time ± 0.150 min and 
symmetric expansion value for chromatograms ± 35.0 ppm. 
Resulting compounds were re-exported to Mass Profiler 
Professional software for peak alignment and data cleanup. 
The signals from the run using HILIC column and negative 
ionization were excluded from the analysis due to poor data 
quality. The number of removed potential compounds was 
292 out of total 2547 potential compounds, resulting in 2255 
potential compounds left for further analysis.
Moreover, we used MS-DIAL ver.2.90 for metabolite 
identification against exact mass, retention time and MSMS 
spectra found in our in-house standard library, internal data-
base found in MS-DIAL and Metlin (https ://metli n.scrip 
ps.edu). Identifications based on in-house library, in which 
commercial and synthetized compounds have been analyzed 
using same method and machinery, received identification 
level of 1. Identification against public libraries received 
identification level 2. Molecular features where we could 
identify the class of the compound, but not the exact metabo-
lite, received identification level 3. Molecular features with 
significant differences between study groups and/or time 
points with MSMS data but no identification are marked 
with identification level 4 (unknown).
At the time of the study, the performance of the QCs 
was not assessed numerically, but the performance has been 
assessed post-hoc for the molecular features discussed or 
visualized in this paper. We used quality metrics defined 
by Broadhurst et al. (2018) to assess the performance of 
the QCs. In brief, relative standard deviation (RSD, also 
known as coefficient of variation) measures the spread 
in feature abundance in the QCs, while D-ratio measures 
the spread in QCs relative to the spread in the biological 
samples. RSD* and D-ratio* are robust alternatives for the 
measures, based on median instead of mean. The averages 
for each quality metric in the presented features are: RSD: 
0.194, RSD*0.123, D-ratio: 0.286, D-ratio*: 0.269. Broad-
hurst et al. suggest a limit of 0.2 for RSD and a limit of 0.4 
for D-ratio, so on average, the data presented here is of high 
quality, although some of the features do not satisfy these 
criteria. The following procedures were all conducted sepa-
rately for each metabolite.
Inverse normal transformation was applied to approxi-
mate a normal distribution of metabolite concentrations. 
Discriminative features between healthy controls and PE 
women, as well as discriminative features between early and 
late pregnancy were discovered using linear mixed effects 
models. Metabolite levels were used as the dependent vari-
able, predicted by early/late pregnancy, PE and the interac-
tion between these two as fixed effects. Subject identifier 
was used as a random effect to account for inter-individual 
variation.
Multiple parameters showed statistically significant dif-
ferences between the study groups. Thus, we investigated 
how the results on relevant metabolites change when the 
unmatched subject parameters are added as covariates to the 
linear mixed models. The covariates we added were parity, 
SGA, gestational weeks, mode of birth, pregestational diabe-
tes mellitus, gestational diabetes mellitus, chronic hyperten-
sion, birth weight, relative birth weight, systolic blood pres-
sure at first visit, highest systolic blood pressure, diastolic 
blood pressure at first visit, and highest diastolic blood pres-
sure. False discovery rate (FDR) was used to adjust p-values 
for multiple comparison. The analyses were performed by 
using the R Project for Statistical Computing version 3.3.3 
and speedglm R package version 0.3–1 (R Core Team 2015; 
Enea 2015).
The Pearson’s correlations were calculated with birth 
weight of newborn and main findings of the maternal 
metabolites.
3  Results
3.1  Clinical data
Maternal and fetal characteristics in PE and control groups 
are presented separately for early and late pregnancy in the 
Table 1. There were no differences in maternal age or body 
mass index (BMI) between the PE and control groups. PE 
women had higher systolic and diastolic blood pressure and 
proteinuria as expected according to the diagnostic criteria 
for PE. The proportion of nulliparous women was higher in 
the PE group compared with the control group. Some PE 
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women also suffered from pre-existing diseases (e.g. chronic 
hypertension, pregestational diabetes) and gestational diabe-
tes. PE women had also more caesarean deliveries than con-
trol women. The newborns of the PE pregnancies were born 
earlier and had smaller absolute and relative birth weights 
(Table 1). There was no difference in the sex distribution of 
newborns. When compared to whole FINNPEC population 
(n = 2515, Jääskeläinen et al. 2016), there were greater pro-
portion of early-onset PE (18.0% vs. 30.4%), women with 
chronic hypertension (26.1% vs. 17.9%) and pregestational 
diabetes (8.7% vs. 3.2%) in the current study.
3.2  Metabolite profiling
In the metabolite profiling analysis, we observed altogether 
1288 molecular features with p-value < 0.05 when compar-
ing samples from early to late pregnancy. After FDR cor-
rection for multiple testing, 1183 molecular features dif-
fered between samples from early to late pregnancy with a 
p-value < 0.05 (Supplementary Table 1).
Figure  1 illustrates the identified metabolites that 
increased during pregnancy in the two groups. Particularly 
following metabolite groups were observed to increase: 
phosphatidylethanolamines and -cholines; amino acids 
(asparagine, threonine, proline, methionine) and bile acids 
Table 1  Maternal and fetal characteristics in pre-eclamptic (PE) and control groups separately for early and late pregnancy
Level of significance for bolded values is p < 0.05
Chronic hypertension was defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg detected before 20 weeks 
of gestation. Gestational hypertension was defined as blood pressure ≥ 140/90 without proteinuria
SD birth weight and height converted to standard deviation scores, SGA small-for-gestational age
a Non-parametric test was used





PE Control p PE Control p
n 46 53 57 14
Gestational week at serum sampling 12 ± 1 (mean ± S.D) 12 ± 1 0.073 35 ± 4 39 ± 1 0.006
Age at delivery, year 31.4 ± 4.6 30.9 ± 4.5 0.997a 31.2 ± 4.5 32.0 ± 3.4 0.380
Nulliparous (%) 35 (76.1%) 23 (43.4%) 0.001 40 (70.2%) 5 (35.7%) 0.028
BMI, kg/m2 (self-reported, pre-pregnancy) 25.7 ± 4.5 25.4 ± 2.4 0.679 25.6 ± 4.4 24.0 ± 3.1 0.196
Systolic blood pressure at first antenatal visit, mm Hg 124 ± 15 117 ± 9 0.010 124 ± 15 117 ± 8 0.067
Diastolic blood pressure at first antenatal visit, mm Hg 80 ± 11 72 ± 8  < 0.001 81 ± 10 71 ± 7 0.002
Early onset of PE  (delivery ≤ 34 + 0 weeks of gesta-
tion)
14 (30.4%) – – 42 (73.7%) – –
Preterm delivery (≤ 37 + 0 weeks of gestation 19 (41.3%) 0 (0.0%)  < 0.001 20 (35.1%) 0 (0.0%) 0.007a
Highest systolic blood pressure, mm Hg** 169 ± 15 124 ± 9  < 0.001a 169 ± 14 125 ± 9  < 0.001a
Highest diastolic blood pressure, mm Hg 112 ± 12 84 ± 6  < 0.001a 111 ± 11 82 ± 6  < 0.001a
Proteinuria (maximum), g/24 h 4.6 ± 4.1 – – 4.2 ± 3.8 – –
Chronic hypertension 12 (26.1%) 0 (0.0%)  < 0.001b 14 (24.6%) 0 (0.0%) 0.057b
Gestational diabetes mellitus 7 (15.2%) 0 (0.0%) 0.004b 11 (19.3%) 0 (0.0%) 0.106b
Pregestational diabetes mellitus 4 (8.7%) 0 (0.0%) 0.043b 5 (8.8%) 0 (0.0%) 0.575b
Mode of delivery  < 0.001 0.185
 Vaginal 24 (52.2%) 47 (88,7%) 30 (52.6%) 9 (64.3%)
 Caesarean section 22 (47.8%) 6 (11.3%) 27 (47.4%) 5 (35.7%)
Fetal characteristics
 Birth weight, g 2435 ± 1003 3627 ± 428  < 0.001a 2602 ± 1010 3644 ± 467  < 0.001a
 Relative birth weight, SD − 1.3 ± 1.4 0.1 ± 0.9  < 0.001 − 1.1 ± 1.5 0.2 ± 0.9 0.002
 SGA 11 (23.9%) 0 (0.0%)  < 0.001 12 (21.1%) 0 (0.0%) 0.106
 Gestational weeks 36 ± 4 40 ± 1.4  < 0.001a 36 ± 4 39 ± 1 0.001a
 Sex 0.035 0.139
  Girl 28 (60.9%) 21 (39.6%) 34 (59.6%) 5 (35.7%)
  Boy 18 (39.1%) 32 (60.4%) 23 (40.4%) 9 (64.3%)
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(glycocholic acid and taurocholic acid). Furthermore, 
metabolites associated with caffeine metabolism (caffeine, 
trigonelline and paraxanthine) were detected to be elevated. 
Hippuric acid was also increased. The greatest increases of 
individual metabolites were detected in phosphatidylethano-
lamines, methionine and cortisone (Fig. 1).
The identified metabolites that decreased during preg-
nancy in the two groups are depicted in Fig. 2. The metab-
olites included following metabolite groups: lysophos-
phatidylcholines (LPCs), lysophosphatidylethanolamines 
(LPEs), branched-chain amino acids (valine and leucine), 
trimethylated compounds, (choline, glycine betaine) and 
carnitines (octanoyl-carnitine and l-carnitine). In addition, 
tryptophan decreased in both groups.
There were altogether 398 molecular features in which 
changes differed between PE and controls groups from 
early to late pregnancy with a p-value < 0.05. Of these, 
47 were identified at level 1 and 2. 42 of the 398 fea-
tures remained significant after FDR correction and three 
of these were identified with confidence level 1 and 2 
(Fig. 3). These three significantly increased metabolites 
were monoacylglyceride 18:1 (MAG 18:1), urea and glyc-
erophosphocholine (GPC) (Fig. 4). Levels of MAG 18:1 
and urea increased in PE women, whereas there were no 
changes in the serum of control women. Furthermore, 
choline derivative, GPC levels decreased in control and 
increased in PE women.
We also investigated how the results on GPC, MAG 
and urea change when the unmatched subject parameters 
are added as covariates to the linear mixed models. The 
results are presented in Table 2. For GPC, the covariates 
explained approximately 13% of the effect, but the p-value of 
the regression coefficient remained below 0.001. For MAG 
Fig. 1  Metabolites increased in pre-eclamptic and control women 
from early to late pregnancy. All metabolites shown are significant 
after false discovery rate correction for multiple testing. Cohen’s d 
values when compared to early pregnancy control samples and raw 
p-values from linear mixed model analysis are shown. The d-value 
shows the mean difference divided by standard deviation compared 
to mean metabolite level in the control group 1st trimester samples. 
Positive d-value means that the increased, and negative that they 
were decreased, when compared to the 1st trimester samples from the 
control group. The level of identifications for each metabolite can be 
found in the Supplementary Table 1. PE phosphatidylethanolamine, 
PC phosphatidylcholine, ACar acylcarnitine, LPE lysophosphatidyle-
thanolamine, FA fatty acid, DAG diacylglyceride
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and urea, adding covariates to the model did not change the 
results significantly.
The strongest negative correlations with birth weight 
of newborn and maternal metabolite were detected with 
between following LPCs: LPC 20:4 (r = − 0.55, p < 0.001), 
LPC 20:3 (r = − 0.51, p < 0.001), LPC 22:4 (r = − 0.51, 
p < 0.001), LPC 22:3 (r = − 0.55, p < 0.001), LPC 22:6 
(r = − 0.52, p < 0.001), LPC 20:4 (r = − 0.55, p < 0.001). 
In addition, there was negative correlation between birth 
weight and carnitine (r = − 0.62, p < 0.001) and palmitoyl-
carnitine (r = − 0.42, p < 0.001). The strongest positive cor-
relations were observed between birth weight and cortisol 
(r = 0.58, p < 0.001) and cortisone (r = 0.59, p < 0.001).
4  Discussion
Our work describes systemic metabolic changes PE and 
healthy pregnant women in early and late pregnancy. Pro-
gression of pregnancy from first to third trimester had large 
scale effects to the serum metabolite profile highlighting the 
remarkable dynamic and adaptive processes occurring in 
maternal metabolism. The differences in metabolic changes 
between PE women and healthy controls in early and in late 
pregnancy were relatively modest. Only urea, MAG 18:1 and 
GPC were identified to be increased in PE when compared 
with control pregnancies.
Particularly following metabolite groups were observed 
to be increased in both PE and control groups: phosphati-
dylethanolamines and –cholines, amino acids and bile 
acids. Metabolites associated with caffeine metabolism 
Fig. 2  Metabolites decreased in pre-eclamptic and controls groups 
from early to late pregnancy. All metabolites shown are significant 
after false discovery rate correction for multiple testing. Cohen’s d 
values when compared to early pregnancy control samples and raw 
p-values from linear mixed model analysis are shown. The d-value 
shows the mean difference divided by standard deviation compared 
to mean metabolite level in the control group 1st trimester samples. 
Positive d-value means that the increased, and negative that they 
were decreased, when compared to the 1st trimester samples from the 
control group. The level of identifications for each metabolite can be 
found in the Supplementary Table 1. PE phosphatidylethanolamine, 
PC phosphatidylcholine, ACar acylcarnitine, LPE lysophosphatidyle-
thanolamine, LPC lysophosphocholine, FA fatty acid
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Fig. 3  Metabolites in which changes differed in PE and controls 
groups from first to third trimester. Raw p-value is shown, metabo-
lites with significant p-values after FDR correction for multiple test-
ing are shown in black. Cohen’s d values when compared to 1st tri-
mester control samples and raw p-values from linear mixed model 
analysis are shown. The d-value shows the mean difference divided 
by standard deviation compared to mean metabolite level in the con-
trol group 1st trimester samples. Positive d-value means that the 
increased, and negative that they were decreased, when compared 
to the 1st trimester samples from the control group. The level of 
identifications for each metabolite can be found in the Supplemen-
tary Table  1. PE phosphatidylethanolamine, PC phosphatidylcho-
line, ACar acylcarnitine, LPE lysophosphatidylethanolamine, LPC 
lysophosphocholine, FA fatty acid, MAG monoacylglyceride
Fig. 4  Metabolites in which 
changes differed significantly 
between PE and control groups 
from early to late pregnancy. 
Mean and 95% confidence 
intervals are shown. MAG 
18:1, monoacylglyceride 18:1 
(level of identification: 1); GPC, 
glycerophosphocholine (level of 
identification: 1); urea (level of 
identification: 2)
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were elevated as well. Furthermore, hippuric acid was 
increased. The greatest increases of individual metabolites 
were detected in phosphatidylethanolamines, methionine 
and cortisone.
Phosphatidylethanolamines are the second most abun-
dant phospholipids in mammalian cells (Patel and Witt 
2017). They have critical role in energy metabolism, they 
are especially abundant in the inner mitochondrial mem-
brane. Furthermore, they assists in the folding of certain 
membrane proteins, are required for the activity of several of 
the respiratory complexes. The changes in the levels of phos-
phatidylethanolamines and/or -cholines in various tissues are 
implicated in metabolic disorders, such as atherosclerosis, 
insulin resistance and obesity (van der Veen et al. 2017). To 
our knowledge, there are no previous data available describ-
ing their exact role in pregnancy. However, since the mito-
chondrial oxidation of fatty acids is known to be essential 
for meeting the fetal energy needs, the increased levels of 
phosphatidylethanolamines may indeed be critical over the 
course of pregnancy when physiological insulin resistance 
occurs. Previously, Colleoni et al. (2010) have shown that 
there is a progressive decrease of mitochondrial DNA con-
tent in blood of pregnant women across uncomplicated ges-
tation compared to nonpregnant women. Thus, it could be 
speculated that the increase in phosphatidylethanolamines 
is not explained by the changed number of mitochondria.
The decreased maternal carnitine levels in the cur-
rent study might reflect the enhanced fetal mitochondrial 
β-oxidation processes. This is in line with previous obser-
vations reported in uncomplicated pregnancies suggesting 
enhanced oxidative activity across gestation (Luan et al. 
2014; Lindsay et al. 2015). Carnitine is also required by 
the fatty acid oxidation in the placental-fetal unit which 
is thought to be primarily met through placental carnitine 
uptake from the maternal circulation (Grube et al. 2005). 
This may further contribute to the reduction in maternal 
plasma carnitine levels throughout pregnancy.
Two bile acids, glycocholic and taurocholic acid were 
shown to be increased. A gradual increase in serum bile 
acid levels is a known feature of metabolic adaptations dur-
ing pregnancy (McIlvride et al. 2017). Several studies have 
previously provided evidence that during normal pregnancy, 
women develop sub-clinical cholestasis (Lunzer et al. 1986, 
Pascual et al. 2002). A very recent paper demonstrated that 
conjugated bile acids including glycocholic and taurocholic 
acid eventually represent the majority of total bile acids as 
the pregnancy proceeds (Zhu et al. 2019). These changes 
are likely related to changes in energy metabolism and gut 
microbiota associated with normal physiology of pregnancy.
In the current study, metabolites associated with caf-
feine metabolism were also increased (caffeine, trigonelline 
and paraxanthine). It is known that half-life of caffeine is 
increased during pregnancy (Knutti 1982). Furthermore, 
maternal caffeine intake has been reported to be associated 
with a reduction in birth weight, however, the precise level 
of intake above which the risk is increased remains unknown 
(Sengpiel et al. 2013). To our knowledge, paraxanthine and 
trigonelline have not specifically been reported in preg-
nancy. However, it is known that paraxanthine is the primary 
metabolite of caffeine and trigonelline performs well as a 
marker of coffee intake (Midttun et al. 2018).
Hippuric acid is another interesting metabolite related to 
dietary intake. It is typically increased with increased con-
sumption of phenolic compounds (tea, wine, fruit and veg-
etables) (Krupp et al. 2012). Furthermore, it is a well-known 
mammalian-microbial cometabolite as it is produced in liver 
from benzoic acid via glycine conjugation (Lees et al. 2013). 
Thus, the observed increase might also reflect changes in 
microbiome composition and/or liver metabolism that take 
place during gestation. To our knowledge, there are only few 
studies reporting hippuric acid levels in pregnancy. Austdal 
et al. (2015) have shown that reduced hippurate excretion in 
urine samples precede PE. In addition, there is one old study 
that has reported hippuric acid in pregnancy (Hirsheimer 
1935). Serum hippuric acid has also been shown to cor-
relate with fasting C‐peptide levels (Luo et al. 2016), and 
thus one could speculate that this might serve as a marker of 
enhanced insulin secretion in pregnancy as well.
Asparagine, threonine, proline, methionine were the 
amino acids that increased in both PE and healthy pregnan-
cies. It is known that maternal amino acids are considered to 
be key determinants for fetal growth (Liu and Arany 2014). 
However, information on maternal amino acids during preg-
nancy is quite limited and comes from studies with only 
small numbers of participants (Cetin 2005; Rossary et al. 
2014). Of the individual amino acids, methionine increased 
Table 2  The proportion of the effect explained by the covariates (the difference between the unadjusted and adjusted regression coefficient, 













GPC 1.348 1.173 0.129600 1.732E−04 9.515E−04
MAG 1.393 1.368 0.018240 7.61E−06 1.134E−05
Urea 1.3 1.294 0.004041 1.34E−05 2.00E−05
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most in the both groups. Methionine is an essential amino 
acid and not only contribute to protein mass, but is also a 
key component in one carbon metabolism. (Dasarathy et al. 
2010). Methionine provides the one carbon units for the 
numerous methyl transferase reactions participating in key 
metabolic reactions like DNA synthesis and thus, in preg-
nancy it could be expected the levels to be increased for the 
needs of growing fetus (Kalhan 2016).
The identified metabolites that decreased during preg-
nancy included LPCs, LPEs, branched-chain amino acids, 
trimethylated compounds and carnitines (octanoyl-carnitine 
and l-carnitine). In addition, tryptophan decreased in both 
groups.
LPCs are biologically active lipids that comprise a major 
class of lipids in human plasma. Previously, LPCs in cord 
blood have been shown to be positively associated with birth 
weight (Robinson et al. 2018; Hellmuth et al. 2017). The 
decreased maternal levels and negative correlations with 
birth weight observed in the current study might reflect the 
increased fetal need of LPCs. Interestingly, increased levels 
of LPCs have also been defined as indicators of metabolic 
health in obesity, as LPCs appear to have glucose-lowering 
and anti-inflammatory effects (Lehmann et al. 2013). How-
ever, their specific role in pregnancy remain to be elucidated.
Branched-chain amino acids, valine and leucine, 
decreased in both groups. There is indeed previous evi-
dence to suggest that branched-chain amino acid metab-
olites, as well as the branched-chain amino acids them-
selves, contribute to insulin resistance and metabolic 
dysfunction (Lynch and Adams 2014). Furthermore, it 
is known that there is a large placental utilization of the 
branched-chain amino acids, some of which are transami-
nated to alpha ketoacids (Manta-Vogli et al. 2020).
The depleted maternal levels of trimethylated com-
pounds, choline, glycine betaine may typically reflect 
generally the fetus’s high demand for methyl donors, as 
has been suggested earlier (Visentin et al. 2015). We have 
previously reported a clear increase in various trimethyl-
ated compounds particularly in cord plasma of the new-
borns of PE mothers (Jääskeläinen et al. 2018). Increased 
fetal choline level might also be associated with higher 
phospholipid demand for the fetus brain development dur-
ing later periods of pregnancy (Zeisel 2006).
We identified three metabolites in which changes dif-
fered significantly between the PE and the control groups 
from early to late pregnancy. Increased levels of both 
MAG 18:1 and GPC may highlight the previous findings 
that there may be a characteristic lipid metabolism in 
women with PE (De Oliveira et al. 2012).
To our knowledge, the specific increase of MAG18:1 
in PE mothers has not been reported before. Romanow-
icz and Bańkowski (2009) have presented the individual 
MAG-fractions in umbilical cord artery wall of newborns 
of PE mothers, and one of the most common unsaturated 
fatty acids occurring in MAG, was C18:1. It is well known 
that adaptation of a maternal lipid metabolism takes place 
throughout gestation. Villa et al. (2009) have observed that 
free fatty acids including oleic acid are higher in women 
with PE. Several characteristics of PE, such as increased 
insulin resistance, disturbed endothelial cell function and 
altered production of vasoactive substances, may be influ-
enced by high concentrations of FFAs. However, the role 
of MAG 18:1 in PE remain to be elucidated.
GPC is a choline derivative and one of the two major 
forms of choline storage (along with phosphocholine) in 
the cytosol. GPC play an important role in the structural 
integrity of cell membranes (Klein 2000). Its increase may 
suggest a protective mechanism against cell damage which 
could also be a consequence of the oxidative stress present 
in PE (Aouache et al. 2018).
Increased levels of urea are known to be increased in 
women with PE (Roopnarinesingh and Morris 1971). 
Earlier, we have also observed increased levels of urea, 
creatine, creatinine, homocitrulline and guanidinopro-
pionate in the cord plasma samples of the PE newborns 
(Jääskeläinen et al. 2018). This may indicate altered func-
tion of the urea cycle in both women with PE mothers and 
their newborns. It is possible that these changes reflect a 
derangement in the mechanism required for the elimina-
tion of these metabolites from the maternal and/or the fetal 
compartment.
Our study had several strengths. First, it is the one of the 
few studies to utilize non-targeted LC–MS method investi-
gating healthy and PE pregnancy. Very recently Sovio et al. 
(2020) conducted a case–cohort study to analyse untargeted 
maternal serum metabolomics in samples from 12, 20, 28 
and 36 weeks of gestational age in women with pre-eclamp-
sia delivering at term and pre-term. Interestingly, they 
observed 4-Hydroxyglutamate and C-glycosyltryptophan 
to be independently predictive at 36 weeks of gestation of 
term PE. Furthermore, Sander et al. (2019) have performed 
non-targeted metabolomics on plasma samples from PE and 
healthy pregnant women but the samples were available only 
in the third trimester. Interestingly, they also observed simi-
lar metabolites to contribute to metabolic disturbances of PE 
women (e.g. bile and amino acids). Previous studies have 
mainly focused on targeted metabolites but not overall pro-
filing of maternal serum or plasma. Luan et al. (2014) have 
investigated healthy women throughout pregnancy but there 
were no multiple collection of samples for the same subject, 
thus study reflected mostly inter-subject variability. Lind-
say et al. (2015) have prospectively followed non-diabetic 
women from first trimester until the end of their pregnancy 
but they used targeted metobolomic technique only. In a 
very recent study, Zhao et al. (2019) performed a longitu-
dinal (first to second trimester) non-targeted metabolomics 
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evaluation of GDM women compared with healthy pregnant 
women. However, in future it would be valuable to obtain 
longitudinal data from all trimesters since there are signifi-
cant alterations occurring in maternal metabolism in late 
pregnancy as well (Lain and Catalano 2007). One limitation 
of our study is that we had limited number of serum avail-
able and only very few samples from the second trimester. 
This was due to fact that serum samples were originally 
available only from a subset and have already been utilized 
in the previous FINNPEC studies. Furthermore, there were 
various exclusion criteria (e.g. smoking) for the current 
study. However, current samples were good representative 
of the whole FINNPEC population (Jääskeläinen et al. 2016) 
although there were greater proportion of early-onset PE, 
women with chronic hypertension and pregestational dia-
betes in the current study, thus probably representing more 
severe form of the disease. In addition, another limitation 
is the observational nature of the study, which complicates 
causal interpretation of the results. Furthermore, one could 
also speculate that difference in gestational weeks at late 
pregnancy serum sampling might have affected the results.
Another challenge with PE is that the condition is heteroge-
neous in origin, which results in considerable variation in the 
clinical presentation. Due to the mixed population, the results 
of this study are especially meaningful for the characterisation 
of the PE syndrome but not necessarily for the etiology of 
the disease. Furthermore, it might be that the participants of 
FINNPEC represent a more severe end of the disease since the 
recruitment occurred at university hospitals only.
It should also be noted that the changes described in 
maternal metabolism across pregnancy may reflect changes 
in placental metabolism (Dunn et al. 2012). Furthermore, the 
metabolome is affected by genetic, dietary and environmental 
contributors (Kadakia et al. 2019). We were not able to control 
for all of these confounding factors. In future, particularly suf-
ficient dietary data would be useful since some of the metabo-
lites we detected appeared to be related to dietary intake.
We conclude that LC–MS based non-targeted technology is 
crucial for gaining understanding of complexity of metabolic 
changes across gestation. In a cohort of women with PE and 
healthy pregnant women, we demonstrated that metabolic sig-
natures from early to late pregnancy are largely shared. Our 
study highlights the need of large-scale longitudinal metabo-
lomic studies in uncomplicated pregnancies before we could 
provide more detailed understanding of metabolism in adverse 
outcomes such as in PE. Our findings are one of the first steps 
for a broader metabolic understanding of the physiological 
changes caused by pregnancy per se.
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